Quest Diagnostics, Inc. (NYSE:DGX)

CAPS Rating: 4 out of 5

A provider of diagnostic testing, information and services, providing insights that enable physicians and other healthcare professionals to make decisions to improve health.

Results 1 - 20 of 75 : 1 2 3 4 Next »

Recs

0
Member Avatar LowEnterpriseVal (22.41) Submitted: 5/17/2014 10:56:51 PM : Outperform Start Price: $57.67 DGX Score: +2.49

On the rec or Kirk Spano.

Recs

0
Member Avatar line70day (< 20) Submitted: 2/28/2014 2:51:57 PM : Outperform Start Price: $52.51 DGX Score: +12.22

World leader in diagnostic information services business. Leading provided in the US of routine and gene based and ecoteric testing services provider interoperable technologies that help health care organizations and physicians enter share and access clinical information. Provid automated patient appointed scheduling customer s at the center of everything thry do. Also have services outside the U S

Recs

0
Member Avatar healthcarevalue (97.34) Submitted: 2/24/2014 8:38:23 PM : Outperform Start Price: $53.00 DGX Score: +10.52

Low price earnings of just under 10. Increasing trend of return on invested capital (ROIC) lately, about 10 percent past year. Debt equity is a bit higher than I'd like, at 0.81, but it's a growing industry, good company, and the low price earnings is attractive.

Recs

0
Member Avatar MWillou (33.50) Submitted: 12/20/2013 9:33:02 AM : Underperform Start Price: $51.92 DGX Score: -10.38

Near-term reimbursement decreases from ACA and regular decreases in Medicare fee schedule. Theranos accepts 50% of the Medicare rate, and process is much more patient friendly; this is the real threat to DGX and LH.

Recs

0
Member Avatar fools4him (78.77) Submitted: 12/17/2013 11:35:34 AM : Outperform Start Price: $52.78 DGX Score: +7.00

Value, over sold

Recs

0
Member Avatar oncqueen (67.92) Submitted: 10/17/2013 9:56:26 AM : Outperform Start Price: $56.93 DGX Score: -6.00

Part of the way the healthcare company CEOs can make 30 million a year is to chisel a bit off contracted lab fees to places like this.

Recs

0
Member Avatar 1smallfry (65.05) Submitted: 7/26/2013 11:40:18 PM : Outperform Start Price: $57.25 DGX Score: -8.68

Yes

Recs

1
Member Avatar GirlScoutDad (96.29) Submitted: 7/20/2013 7:18:34 PM : Outperform Start Price: $57.74 DGX Score: -9.10

I am making an educated guess that medical diagnostic testing will expand along with the aging of the boomer generation, and that testing for opiate and other controlled medications will increase as well. Quest is a bet on this trend.

Recs

0
Member Avatar DrLinks (33.23) Submitted: 7/19/2013 10:54:48 PM : Outperform Start Price: $57.74 DGX Score: -9.10

All plays on H.C are sage IMO as Obamacare is going to do the complete opposite of its' stated mission of driving costs down. THEY WILL BE DRIVEN UP, and any/all companies in the H.C.sector related to O-Sham-A-Care stand to profit handsomely.

Recs

0
Member Avatar AnsgarJohn (99.04) Submitted: 5/31/2013 6:34:28 AM : Outperform Start Price: $60.58 DGX Score: -17.04

CAPS player MJKPayday

Recs

1
Member Avatar bclan13 (99.01) Submitted: 3/19/2013 9:00:25 PM : Underperform Start Price: $54.73 DGX Score: +13.63

Continue to lose share to hospital labs as hospitals become more integrated. Also a target for reimbursement rate reductions because lab services may be viewed as commodities that payers can source from the lowest bidder.

Recs

0
Member Avatar Orthonormal (87.75) Submitted: 3/4/2013 12:27:49 PM : Outperform Start Price: $54.13 DGX Score: -15.55

Magic formula pick

Recs

1
Member Avatar 42asdf (48.91) Submitted: 1/30/2013 8:52:52 PM : Outperform Start Price: $56.57 DGX Score: -22.16

Low p/e p/b and p/s with solid profits dividends and return of equity. It has quite a bit of debt (debt to equity of .8), but still has decent cash flow. No real growth.

Recs

0
Member Avatar srkenne264 (99.56) Submitted: 6/30/2011 1:57:43 PM : Outperform Start Price: $56.43 DGX Score: -40.03

babo

Recs

0
Member Avatar MJKpayday (99.76) Submitted: 5/29/2011 7:13:12 AM : Outperform Start Price: $55.06 DGX Score: -34.02

Price/Share - 1.4
Price/Earnings - 15
Price/Book - 2.6

Over the last 10 years or so Quest has never traded below these multipliers. So if Quest Diagnostics performance on par with S&P500 and there is just a slight multiple expansion towards the more typical than Quest will probably be outperforming the Price of S&P.

Recs

1
Member Avatar zycantodan (90.34) Submitted: 3/7/2011 11:26:23 AM : Outperform Start Price: $53.33 DGX Score: -33.92

Clean facilities and well-integrated IT systems from the patient side - you can schedule appointments online and find locations easily. This significantly cuts down on in-office wait time. All labeling is automated and efficient. I would assume the back-office IT is run as smoothly as the customer-facing side to allow for more efficiencies, but I could be wrong. Appears cheap/similar-price relative to peers although it is the dominant player. With aging population need for DGX services will increase

Recs

0
Member Avatar Imperial1964 (97.79) Submitted: 10/29/2010 8:38:18 PM : Outperform Start Price: $46.61 DGX Score: -32.88

Piotroski screen.

Also fits my criteria fairly well, except for the debt/equity ratio.

Recs

0
Member Avatar olivetree1951 (< 20) Submitted: 10/22/2010 2:19:32 PM : Underperform Start Price: $46.27 DGX Score: +33.09

It is a tale of over-optimism to think ObamaCare won't go after medical laboratories and medical device makers. Quest is in a duopoly with LabCorp in the testing market in the US and the press on margins doesn't bear well for either.

Recs

0
Member Avatar tekwatchlist (94.16) Submitted: 9/22/2010 3:20:50 PM : Outperform Start Price: $44.98 DGX Score: -42.35

Added 8/12/10

Recs

0
Member Avatar tekennedy (72.21) Submitted: 8/17/2010 7:02:24 PM : Outperform Start Price: $44.87 DGX Score: -43.14

Strong ROE with ability to grow. I like this company due to its strong competitive position, effectively sharing the market with Labcorp, backed up by strong scale benefits. The company should also experience strong growth due to the oh-so-talked-about baby boomer aging and potential overall medical savings from increased screening. There is the potential of exponential growth in screening with genome based tests, which could help prevent or decrease the negative impact of a large number of major conditions(I see this as more of a built in option as the ability to prediagnose is uncertain in both impact and timing). This company, despite its competitive advantages, runs the risk of a shrinking market if select tests are made easier to perform and can therefore be performed in the doctors office(this distinction is made by a government organization). At its current pricing I believe this company should be able to outpace the S&P in the vast majority of situations.

Results 1 - 20 of 75 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement